Suk Joong Oh

1.4k total citations
40 papers, 1.0k citations indexed

About

Suk Joong Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Suk Joong Oh has authored 40 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Surgery. Recurrent topics in Suk Joong Oh's work include Chronic Myeloid Leukemia Treatments (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (7 papers). Suk Joong Oh is often cited by papers focused on Chronic Myeloid Leukemia Treatments (8 papers), Lymphoma Diagnosis and Treatment (8 papers) and Viral-associated cancers and disorders (7 papers). Suk Joong Oh collaborates with scholars based in South Korea, United States and Thailand. Suk Joong Oh's co-authors include Woo Kyu Jeon, Dong Il Park, Chong Il Sohn, Byung Ik Kim, Hong Joo Kim, Yong Kyun Cho, Seungho Ryu, Antonia R. Sepulveda, Eun Yoon Cho and Jung Won Yun and has published in prestigious journals such as Blood, Cancer and International Journal of Cancer.

In The Last Decade

Suk Joong Oh

39 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Suk Joong Oh South Korea 16 539 423 263 263 145 40 1.0k
Hideya Takeuchi Japan 17 584 1.1× 358 0.8× 223 0.8× 122 0.5× 371 2.6× 70 1.3k
Yoshio Gunji Japan 17 405 0.8× 375 0.9× 374 1.4× 88 0.3× 254 1.8× 46 1.2k
Ryo Wada Japan 20 437 0.8× 321 0.8× 416 1.6× 271 1.0× 225 1.6× 140 1.2k
Shigeki Tomita Japan 18 551 1.0× 230 0.5× 357 1.4× 224 0.9× 262 1.8× 100 1.2k
Chueh‐Chuan Yen Taiwan 19 386 0.7× 377 0.9× 221 0.8× 173 0.7× 203 1.4× 58 930
Keisuke Aiba Japan 15 500 0.9× 284 0.7× 333 1.3× 149 0.6× 194 1.3× 71 992
Vera Schellerer Germany 20 550 1.0× 270 0.6× 294 1.1× 210 0.8× 265 1.8× 60 1.1k
A. Watkinson United Kingdom 9 181 0.3× 286 0.7× 459 1.7× 227 0.9× 144 1.0× 13 1.6k
Toshimichi Asano Japan 21 677 1.3× 452 1.1× 580 2.2× 57 0.2× 260 1.8× 120 1.3k
Yuichi Arimoto Japan 13 376 0.7× 313 0.7× 429 1.6× 102 0.4× 330 2.3× 35 1.0k

Countries citing papers authored by Suk Joong Oh

Since Specialization
Citations

This map shows the geographic impact of Suk Joong Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suk Joong Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suk Joong Oh more than expected).

Fields of papers citing papers by Suk Joong Oh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suk Joong Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suk Joong Oh. The network helps show where Suk Joong Oh may publish in the future.

Co-authorship network of co-authors of Suk Joong Oh

This figure shows the co-authorship network connecting the top 25 collaborators of Suk Joong Oh. A scholar is included among the top collaborators of Suk Joong Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suk Joong Oh. Suk Joong Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lee, Sung‐Eun, Sung-Soo Yoon, Deok‐Hwan Yang, et al.. (2023). P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY. HemaSphere. 7(S3). e86929d8–e86929d8. 1 indexed citations
2.
Lee, So Yeon, Hyun Jung Kim, Yu Ri Shin, et al.. (2016). Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis. European Radiology. 27(6). 2333–2347. 14 indexed citations
3.
Han, Sora, Jeong Su Park, Sunyi Lee, et al.. (2015). CTRP1 protects against diet-induced hyperglycemia by enhancing glycolysis and fatty acid oxidation. The Journal of Nutritional Biochemistry. 27. 43–52. 35 indexed citations
4.
Park, Min Soo, Sung‐Hyun Kim, Suk Joong Oh, et al.. (2015). Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leukemia & lymphoma. 57(8). 1856–1864. 9 indexed citations
5.
6.
Lee, Tae Heon, et al.. (2011). Pure Red Cell Aplasia Caused by Acute Hepatitis A. Chonnam Medical Journal. 47(1). 51–51. 3 indexed citations
7.
Jang, Joung-Soon, Ho Yeong Lim, In Gyu Hwang, et al.. (2009). Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemotherapy and Pharmacology. 65(4). 641–647. 57 indexed citations
8.
Kim, Won Seog, Hyeon Seok Eom, Jin Seok Kim, et al.. (2009). Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial. Investigational New Drugs. 29(1). 154–160. 11 indexed citations
9.
Park, Min Jae, Jeeyun Lee, Jung Yong Hong, et al.. (2009). Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer. 115(7). 1518–1530. 19 indexed citations
10.
Park, Dong Il, Suk Joong Oh, Eun Jung Hong, et al.. (2008). [Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].. PubMed. 51(5). 280–4. 79 indexed citations
11.
Kim, Jong Gwang, Sang Kyun Sohn, Yee Soo Chae, et al.. (2007). Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemotherapy and Pharmacology. 60(1). 129–134. 77 indexed citations
12.
Oh, Sung Yong, Hyuk‐Chan Kwon, Won Seog Kim, et al.. (2007). Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. Cancer Letters. 258(1). 90–97. 15 indexed citations
13.
Kim, Jong Gwang, Sang Kyun Sohn, Hye Jin Kang, et al.. (2007). Consideration of aggressive therapeutic strategies for primary testicular lymphoma. American Journal of Hematology. 82(9). 840–845. 32 indexed citations
14.
Oh, Sung Yong, Baek‐Yeol Ryoo, Won Seog Kim, et al.. (2007). Nongastric marginal zone B‐cell lymphoma: Analysis of 247 cases. American Journal of Hematology. 82(6). 446–452. 35 indexed citations
15.
Park, Dong Il, Suk Joong Oh, Hong Joo Kim, et al.. (2006). HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. International Journal of Colorectal Disease. 22(5). 491–7. 91 indexed citations
16.
Park, Dong Il, Jung Won Yun, Jung Ho Park, et al.. (2006). HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer. Digestive Diseases and Sciences. 51(8). 1371–1379. 265 indexed citations
17.
Oh, Suk Joong, et al.. (2006). A case of neuroblastoma in adult.
18.
Choi, Hyo Sun, et al.. (2004). A case of small bowel Burkitt's lymphoma in AIDS patient. The Korean Journal of Internal Medicine. 66(5). 543–548. 1 indexed citations
19.
Park, Dong Il, Suk Joong Oh, Sungha Park, et al.. (2004). [Clinical significance of HER-2/neu expression in colon cancer].. PubMed. 44(3). 147–52. 7 indexed citations
20.
Oh, Suk Joong. (1969). The rate of cerebral involvement in paragonimiasis: an epidemiological study.. Kiseichūgaku zasshi. 18(2). 211–215. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideya Takeuchi Breakdown of academic impact, for papers by Yoshio Gunji Breakdown of academic impact, for papers by Ryo Wada Breakdown of academic impact, for papers by Shigeki Tomita Breakdown of academic impact, for papers by Chueh‐Chuan Yen Breakdown of academic impact, for papers by Keisuke Aiba Breakdown of academic impact, for papers by Vera Schellerer Breakdown of academic impact, for papers by A. Watkinson Breakdown of academic impact, for papers by Toshimichi Asano Breakdown of academic impact, for papers by Yuichi Arimoto
Rankless by CCL
2026